NCT06392841 2025-10-20
HARMONY
Hoosier Cancer Research Network
Phase 2 Withdrawn
Clinical Trials
12 trialsNCT06527690 2025-09-29
REPRESENTATION
Latin American Cooperative Oncology Group
Phase 2 Withdrawn
NCT05672095 2025-05-23
Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer
City of Hope Medical Center
Phase 1/2 Withdrawn
NCT06365970 2025-02-03
Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers
University of Pittsburgh
Phase 2 Withdrawn
NCT06161493 2024-10-15
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
University of Pittsburgh
Phase 1 Withdrawn
NCT05666349 2024-03-26
RiNG
University College, London
Phase 1 Withdrawn
NCT05238831 2024-01-23
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT05174455 2023-09-18
Niraparib for the Treatment of Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
Phase 2 Withdrawn
NCT05412706 2023-09-08
Bohème
Ospedale Policlinico San Martino
Phase 2 Withdrawn
NCT04895046 2022-06-29
Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma
Hoosier Cancer Research Network
Phase 2 Withdrawn
NCT03806049 2021-07-15
Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Phase 3 Withdrawn
NCT04655183 2021-06-30
Study of M4344 in Combination With Niraparib
EMD Serono
Phase 1/2 Withdrawn